EXHIBIT 10.287 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDED AND...Research, Development and License Agreement • January 13th, 2006 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • California
RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT BETWEEN NEOSE TECHNOLOGIES, INC. AND NOVO NORDISK A/SResearch, Development and License Agreement • March 10th, 2008 • Neose Technologies Inc • Medicinal chemicals & botanical products • Pennsylvania
This RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (“Agreement”), is dated as of November 2, 2007 (the “Effective Date”), between Neose Technologies, Inc., a Delaware corporation (“Neose”), and Novo Nordisk A/S, a Danish corporation (“Novo”).
RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT BETWEEN NEOSE TECHNOLOGIES, INC. AND NOVO NORDISK A/S DATED AS OF NOVEMBER 17, 2003Research, Development and License Agreement • February 17th, 2004 • Neose Technologies Inc • Medicinal chemicals & botanical products • Pennsylvania
This RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (“Agreement”), is dated as of November 17, 2003, between Neose Technologies, Inc., a Delaware corporation (“Neose”), and Novo Nordisk A/S, a Danish corporation (“Novo”).
AMENDMENT NO. 3 TO RESEARCH & DEVELOPMENT AND LICENSE AGREEMENTResearch & Development and License Agreement • August 19th, 2003 • Arqule Inc • Pharmaceutical preparations • Illinois
This Amendment No. 3 to Research & Development and License Agreement, dated as of December 23, 1997, is between Abbott Laboratories, an Illinois corporation having a principal place of business at 100 Abbott Park Road, Abbott Park, Illinois (“Abbott”) and ArQule, Inc., a Delaware corporation having a principal place of business at 200 Boston Avenue, Suite 1000, Medford, Massachusetts (“ArQule”).
AMENDMENT #7 TO THE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTResearch, Development and License Agreement • May 5th, 2016 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This AMENDMENT #7 TO THE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this “Amendment No. 7”) is entered into and made effective as of the 4th day of March, 2016 (the “Amendment No. 7 Effective Date”) by and between Ionis Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 (formerly, “Isis Pharmaceuticals, Inc.”) (“Ionis”), and Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at 980 Great West Road, Brentford London TW8 9GS, United Kingdom (“GGL”), and Glaxosmithkline intellectual property development limited, a company existing under the laws of England and Wales, having its registered office at 980 Great West Road, Brentford London TW8 9GS, United Kingdom (“GSK IPDL”). GGL and GSK IPDL are referred to together as “GSK”. Ionis and GSK are each referred to herein by name or as a “Party” or, collectively, as “Parties.”
AMENDMENT #6 TO RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTResearch, Development and License Agreement • June 10th, 2016 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations
This AMENDMENT #6 TO THE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this “Amendment No. 6”) is entered into and made effective as of the 2nd day of September, 2015 (the “Amendment No. 6 Date”) by and between Isis Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 (“Isis”), and Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at 980 Great West Road, Brentford, London TW8 9GS, United Kingdom (“GGL”), and Glaxosmithkline intellectual property development limited, a company existing under the laws of England and Wales, having its registered office at 980 Great West Road, Brentford London TW8 9GS, United Kingdom (“GSK IPDL”). GGL and GSK IPDL are referred to together as (“GSK”). Isis and GSK are each referred to herein by name or as a “Party” or, collectively, as “Parties.”
AMENDMENT NO. 2 TO RESEARCH & DEVELOPMENT AND LICENSE AGREEMENTResearch & Development and License Agreement • August 19th, 2003 • Arqule Inc • Pharmaceutical preparations • Illinois
This Amendment No. 2 to Research & Development and License Agreement is dated as of December 24, 1996 by and between Abbott Laboratories, an Illinois corporation having a principal place of business at 100 Abbott Park Road, Abbott Park, Illinois (“Abbott”) and ArQule, Inc., a Delaware corporation having a principal place of business at 200 Boston Avenue, Suite 36, Medford, Massachusetts (“ArQule”).
AMENDMENT #1 TO RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTResearch, Development and License Agreement • August 8th, 2011 • Isis Pharmaceuticals Inc • Pharmaceutical preparations
This AMENDMENT #1 TO THE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this “Amendment”) is entered into and made effective as of the 11th day of May, 2011 (the “Amendment Date”) by and between Isis Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 1896 Rutherford Road, Carlsbad, CA 92008 (“Isis”), and Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (“GSK”). Isis and GSK are each referred to herein by name or as a “Party” or, collectively, as “Parties.”
RESEARCH/DEVELOPMENT AND LICENSE AGREEMENTResearch/Development and License Agreement • September 30th, 2002 • Si Diamond Technology Inc • Communications equipment, nec
This Agreement, made and entered into on September 1, 2002 by and between xxxxxxxxxxxxx having its registered office at xxxxxxxxxxxxxxxxxxxx (hereafter referred to as “xxxxx”), and APPLIED NANOTECH, Inc., formerly FEPET, Inc., having its registered office at 3006 Longhorn Blvd., Suite 107, Austin, TX 78758, USA (hereafter referred to as “ANI”), jointly referred to as Parties,
RESEARCH & DEVELOPMENT AND LICENSE AGREEMENTResearch & Development and License Agreement • August 19th, 2003 • Arqule Inc • Pharmaceutical preparations • Illinois
THIS AGREEMENT (“Agreement”) is made and entered into effective as of the 16th day of June, 1995 (“Effective Date”), by and between ABBOTT LABORATORIES, an Illinois corporation having a principal place of business at 100 Abbott Park Road, Abbott Park, Illinois 60064 (“Abbott”) and ARQULE, INC., a Delaware corporation having a principal place of business at 200 Boston Avenue, Suite 3600, Medford, Massachusetts 02155 (‘ArQule”).
FROM: [ILLEGIBLE] PHONE NO. : 00442076811314 13 DEC. 2006 01: 58 PM P1Research, Development and License Agreement • April 15th, 2014 • Xenetic Biosciences, Inc. • Air transportation, nonscheduled
This is an amendment to the Research, Development and License Agreement (“R&L AGREEMENT”) entered into on August 15, 2005, by and between Lipoxen Technologies Limited, a company registered in England and [ILLEGIBLE] with company number 03401495 and having its registered office at suit [ILLEGIBLE] WC1H [ILLEGIBLE] (“LIPOXEN”); [ILLEGIBLE] Healthcare SA (“BHSA”), a corporation organized and existing under the laws of Switzerland, and Baxter Healthcare Corporation (“BHC”) having its principal place of business at One [ILLEGIBLE] Parkway, [ILLEGIBLE], [ILLEGIBLE]
AMENDMENT #6 TO RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTResearch, Development and License Agreement • November 9th, 2015 • Isis Pharmaceuticals Inc • Pharmaceutical preparations
This AMENDMENT #6 TO THE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this “Amendment No. 6”) is entered into and made effective as of the 2nd day of September, 2015 (the “Amendment No. 6 Date”) by and between Isis Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 (“Isis”), and Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at 980 Great West Road, Brentford, London TW8 9GS, United Kingdom (“GGL”), and Glaxosmithkline intellectual property development limited, a company existing under the laws of England and Wales, having its registered office at 980 Great West Road, Brentford London TW8 9GS, United Kingdom (“GSK IPDL”). GGL and GSK IPDL are referred to together as (“GSK”). Isis and GSK are each referred to herein by name or as a “Party” or, collectively, as “Parties.”
FROM: [ILLEGIBLE] PHONE NO. : 00442076811314 13 DEC. 2006 01: 58 PM P1Research, Development and License Agreement • February 18th, 2015 • Xenetic Biosciences, Inc. • Pharmaceutical preparations
This is an amendment to the Research, Development and License Agreement (“R&L AGREEMENT”) entered into on August 15, 2005, by and between Lipoxen Technologies Limited, a company registered in England and Wales with company number 03401495 and having its registered office at Suite 303, Hamilton House, Mabledon Place, London WC1H 9BB (“LIPOXEN”); Baxter Healthcare SA (“BHSA”), a corporation organized and existing under the laws of Switzerland, and Baxter Healthcare Corporation (“BHC”) having its principal place of business at One Baxter Parkway, Deerfield, Illinois 60015 (BNSA and BHC collectively referred to as “BAXTER”).
ContractResearch, Development and License Agreement • August 4th, 2014 • Isis Pharmaceuticals Inc • Pharmaceutical preparations
Amendment Number 3 to the Research, Development and License AgreementResearch, Development and License Agreement • March 8th, 2006 • Neose Technologies Inc • Medicinal chemicals & botanical products
This Amendment Number 3 to the Agreement (as defined below)(the “Amendment”) is effective as of December 15, 2005 (the “Effective Date”), and is by and among Novo Nordisk A/S, a corporation organized and existing under the laws of Denmark, Novo Nordisk Health Care AG, a corporation organized and existing under the laws of Switzerland (collectively, Novo Nordisk A/S and Novo Nordisk Health Care AG are hereinafter referred to as “Novo”), and Neose Technologies, Inc., a corporation organized and existing under the laws of the state of Delaware (hereinafter referred to as “Neose”).
AMENDMENT #5 TO THE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTResearch, Development and License Agreement • August 4th, 2014 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This AMENDMENT #5 TO THE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this "Amendment No. 5") is entered into and made effective as of the 27th day of June, 2014 (the "Amendment No. 5 Effective Date") by and between Isis Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 ("Isis"), and Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at 980 Great West Road, Brentford London TW8 9GS, United Kingdom ("GGL"), and GlaxoSmithKline Intellectual Property Development Limited, a company existing under the laws of England and Wales, having its registered office at 980 Great West Road, Brentford London TW8 9GS, United Kingdom ("GSK IPDL"). GGL and GSK IPDL are referred to together as "GSK". Isis and GSK are each referred to herein by name or as a "Party" or, collectively, as "Parties."
Research, Development, and License Agreement Among Ionis Pharmaceuticals, Inc., And And Hoffmann-La Roche Inc.Research, Development, and License Agreement • November 2nd, 2023 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations
This RESEARCH, DEVELOPMENT, AND LICENSE AGREEMENT (the “Agreement”) is entered into as of the 26th day of September, 2023 (the “Effective Date”) by and among Ionis Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, California 92010 (“Ionis”), F. Hoffmann-La Roche Ltd, a Swiss corporation, having its principal place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche Basel”) and Hoffmann-La Roche Inc., a New Jersey corporation, having its principal place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424 (“Roche US”; Roche Basel and Roche US are collectively referred to as “Roche”). Roche and Ionis each may be referred to herein individually as a “Party” or collectively as the “Parties.”
AMENDMENT #2 TO RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTResearch, Development and License Agreement • February 28th, 2013 • Isis Pharmaceuticals Inc • Pharmaceutical preparations
This AMENDMENT #2 TO THE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this “Amendment”) is entered into and made effective as of the 30th day of October, 2012 (the “Amendment Date”) by and between ISIS PHARMACEUTICALS, INC., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 (“Isis”), and GLAXO GROUP LIMITED, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (“GSK”). Isis and GSK are each referred to herein by name or as a “Party” or, collectively, as “Parties.”
Portions of this exhibit were omitted and filed separately with the Secretary of the Commission pursuant to an application for confidential treatment filed with the Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934. Such...Research, Development and License Agreement • February 17th, 2004 • Neose Technologies Inc • Medicinal chemicals & botanical products
The purpose of this letter is to amend the Agreement in certain respects to reflect our recent discussions. Capitalized terms used and not otherwise defined in this letter are used as defined in the Agreement.
AMENDMENT #8 TO THE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTResearch, Development and License Agreement • November 6th, 2019 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This AMENDMENT #8 TO THE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this “Amendment No. 8”) is entered into and made effective as of the 29th day of July 2019 (the “Amendment No. 8 Effective Date”) by and between IONIS PHARMACEUTICALS, INC., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 (formerly “Isis Pharmaceuticals, Inc.”) (“Ionis”), and GLAXO GROUP LIMITED, a company existing under the laws of England and Wales, having its registered office at 980 Great West Road, Brentford London TW8 9GS, United Kingdom (“GGL”), and GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, a company existing under the laws of England and Wales, having its registered office at 980 Great West Road, Brentford London TW8 9GS, United Kingdom (“GSK IPDL”). GGL and GSK IPDL are referred to together as “GSK”. Ionis and GSK are each referred to herein by name or as a “Party” or, collectively, as “Parties.”
RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT BETWEEN ISIS PHARMACEUTICALS, INC., AND GLAXO GROUP LIMITEDResearch, Development and License Agreement • May 7th, 2010 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (together with all Appendices and Schedules hereto, the “Agreement”) is entered into as of the 30th day of March, 2010 (the “Effective Date”) by and between ISIS PHARMACEUTICALS, INC., a Delaware corporation, having its principal place of business at 1896 Rutherford Road, Carlsbad, CA 92008 (“Isis”), and GLAXO GROUP LIMITED, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (“GSK”). GSK and Isis each may be referred to herein individually as a “Party” or collectively as the “Parties.” The terms used in this Agreement with initial letters capitalized, whether used in the singular or the plural, will have the meaning set forth in APPENDIX 1.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT By and Between AVEO PHARMACEUTICALS, INC. and SCHERING CORPORATION, acting through...Research, Development and License Agreement • December 16th, 2009 • Aveo Pharmaceuticals Inc • New York
This Research, Development and License Agreement (this “Agreement”), dated as of March 23, 2007 (the “Execution Date”), is entered into by and between AVEO PHARMACEUTICALS, INC. (“AVEO”), a Delaware corporation having a principal office at 75 Sidney Street, Cambridge, Massachusetts 02139 U.S.A.; and SCHERING CORPORATION, acting through its Schering-Plough Research Institute division (“Schering-Plough”), a New Jersey corporation having a principal office located at 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 U.S.A. AVEO and Schering-Plough are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTResearch, Development and License Agreement • November 9th, 2005 • Aksys LTD • Electromedical & electrotherapeutic apparatus • New York
THIS AGREEMENT, is effective as of the 24th day of October, 2005 (the “Effective Date”), by and between Aksys, Ltd., a Delaware corporation with its principal offices at Two Marriott Drive, Lincolnshire, Illinois 60069 (hereinafter “Client”), and DEKA PRODUCTS LIMITED PARTNERSHIP, a New Hampshire limited partnership with its principal offices at 340 Commercial Street, Manchester, New Hampshire 03101, and its general partner, DEKA RESEARCH AND DEVELOPMENT CORP., a New Hampshire corporation of the same address (hereinafter “DEKA”).
AMENDMENT #4 TO RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTResearch, Development and License Agreement • August 4th, 2014 • Isis Pharmaceuticals Inc • Pharmaceutical preparations
This AMENDMENT #4 TO THE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this "Amendment No. 4") is entered into and made effective as of the 10th day of April, 2014 (the "Amendment No. 4 Effective Date") by and between Isis Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 ("Isis"), and Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at 980 Great West Road, Brentford London TW8 9GS, United Kingdom ("GSK"). Isis and GSK are each referred to herein by name or as a "Party" or, collectively, as "Parties."
1 EXHIBIT 10.1 CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS. AMENDED AND RESTATED RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT This Agreement, effective as of January...Research, Development and License Agreement • May 14th, 2001 • Arqule Inc • Pharmaceutical preparations • England
Re: Research, Development and License Agreement Between Neose Technologies, Inc. and Novo Nordisk A/S dated as of November 17, 2003, as amended December 18, 2003 and October 12, 2004 (the “Agreement”) (relating to ******)Research, Development and License Agreement • May 3rd, 2005 • Neose Technologies Inc • Medicinal chemicals & botanical products
The purpose of this letter is to amend the Agreement in certain respects to reflect our recent discussions. Capitalized terms used and not otherwise defined in this letter are used as defined in the Agreement. We have agreed as follows:
CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND SEPARATELY FILED WITH THE COMMISSION RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT BETWEEN NEOSE TECHNOLOGIES, INC. AND MACROGENICS, INC. DATED April 26, 2004Research, Development and License Agreement • August 5th, 2004 • Neose Technologies Inc • Medicinal chemicals & botanical products • Delaware
This RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (“Agreement”), is dated April 26, 2004, between Neose Technologies, Inc., a Delaware corporation (“Neose”), and MacroGenics, Inc., a Delaware corporation (“MacroGenics”).
RESEARCH. DEVELOPMENT AND LICENSE AGREEMENTResearch, Development and License Agreement • September 16th, 2014 • Dyadic International Inc • Industrial organic chemicals • Delaware
This RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT made this 6th day of May, 2013, by and among DYADIC INTERNATIONAL (USA), INC., a Florida corporation ("Dyadic USA"), DYADIC NETHERLAND B.V., a company organized under the laws of the Netherlands and a wholly owned subsidiary of Dyadic USA ("DNL") (Dyadic USA and DNL shall hereinafter collectively be referred to as "Dyadic"), and BASF SE, a company organized under the laws of Germany ("BASF').
RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT AMONG NEOSE TECHNOLOGIES, INC. AND NOVO NORDISK A/S AND NOVO NORDISK HEALTH CARE AG DATED AS OF NOVEMBER 17, 2003Research, Development and License Agreement • February 17th, 2004 • Neose Technologies Inc • Medicinal chemicals & botanical products • Pennsylvania
This RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (“Agreement”), is dated as of November 17, 2003, among Neose Technologies, Inc., a Delaware corporation (“Neose”), and Novo Nordisk A/S, a Danish corporation, and Novo Nordisk Health Care AG, a Swiss Corporation (collectively, “Novo”).
